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Abstract
Background: The only licensed malaria vaccine, RTS,S/AS01, has been developed for morbidity-control in young
children. The potential impact on transmission of deploying such anti-infective vaccines to wider age ranges,
possibly with co-administration of antimalarial treatment, is unknown. Combinations of existing malaria
interventions is becoming increasingly important as evidence mounts that progress on reducing malaria incidence
is stalling and threatened by resistance.
Methods: Malaria transmission and intervention dynamics were simulated using OpenMalaria, an individual-based
simulation model of malaria transmission, by considering a seasonal transmission setting and by varying
epidemiological and setting parameters such as transmission intensity, case management, intervention types and
intervention coverages. Chemopreventive drugs and anti-infective vaccine efficacy profiles were based on previous
studies in which model parameters were fitted to clinical trial data. These intervention properties were used to
evaluate the potential of seasonal mass applications of preventative anti-infective malaria vaccines, alone or in
combination with chemoprevention, to reduce malaria transmission, prevent resurgence, and/or reach transmission
interruption.
Results: Deploying a vaccine to all ages on its own is a less effective intervention strategy compared to
chemoprevention alone. However, vaccines combined with drugs are likely to achieve dramatic prevalence
reductions and in few settings, transmission interruption. The combined mass intervention will result in lower
prevalence following the intervention compared to chemoprevention alone and will increase chances of
interruption of transmission resulting from a synergistic effect between both interventions. The combination of
vaccine and drug increases the time before transmission resurges after mass interventions cease compared to mass
treatment alone. Deploying vaccines and drugs together requires fewer rounds of mass intervention and fewer
years of intervention to achieve the same public health impact as chemoprevention alone.
Conclusions: Through simulations we identified a previously unidentified value of deploying vaccines with drugs,
namely the greatest benefit will be in preventing and delaying transmission resurgence for longer periods than
with other human targeted interventions. This is suggesting a potential role for deploying vaccines alongside drugs
in transmission foci as part of surveillance-response strategies.
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Background
In 2015 WHO set new goals of reducing malaria inci-
dence by 90% and eliminating malaria in 35 countries by
2030 [1]. This followed dramatic reductions in malaria
prevalence from 2000 to 2015 [1] due to scale-up of vec-
tor control and artemisinin combination therapy [2].
However, recent estimates indicate that the improve-
ments have stalled, with increasing incidence in several
countries [3], and current interventions and implemen-
tation strategies may not be sufficient. New tools such as
novel insecticides, drugs, and vaccines, are likely to play
a role in interruption of malaria transmission [4] and
continue to be developed. As we wait for novel tools to
be tested and approved, it is important to use existing
tools as effectively as possible to help facilitate the efforts
of 20 countries in achieving their goal of malaria elimin-
ation in the next 7 years as documented by WHO [1].
Increased funding and greater access to interventions,
such as effective case management and vector control
tools, are essential; it is also increasingly important to
innovate the deployment of combinations of existing
interventions.
There is just one malaria vaccine that has successfully
completed Phase 3 clinical studies, RTS,S/AS01, a pre-
erythrocytic or anti-infective vaccine (AIV), targeting
sporozoite stages of the Plasmodium falciparum life
cycle. RTS,S/AS01 received a positive opinion from the
European Medicines Agency in 2015 [5], and pilot im-
plementation via routine childhood immunization in re-
gions of Ghana, Kenya and Malawi have started earlier
this year [6]. From extensive analysis of Phase 3 trials
the vaccine was estimated to have a high initial efficacy,
with protection waning over time [7, 8]. Recently pub-
lished data showed that an altered regimen of RTS,S in
which the third dose is delayed and given at a fraction of
the original dosage (delayed, fractional dose RTS,S) re-
sults in a higher efficacy in human challenge trial [9]
and thus may result in a longer duration of protection,
although this still needs to be confirmed in the field.
There are many vaccines in development targeting
sporozoite, liver, blood, or mosquito stages of the mal-
aria parasite, including AIVs such as the delayed frac-
tional dose RTS,S, the whole Plasmodium falciparum
sporozoite based PfSPZ Vaccine [10, 11], and R21 [12].
A vaccine which can confer many years of protection is
desirable but in addition to technical and regulatory
challenges there may be biological hurdles that cannot
be easily overcome.
Clinical development of RTS,S focused on reducing
morbidity and mortality, especially in young children,
the rationale being to add additional protection to vector
control for the vulnerable population experiencing the
highest burden of disease. Modeling studies informed by
clinical trial results estimated that, despite waning
protection over time, routine immunization of children
with RTS,S is likely to have a positive public health im-
pact [13]. Given that duration of protection from RTS,S
immunization is shorter than expected, but longer than
chemoprevention, alternative uses of the vaccine as a
yearly seasonal intervention targeting children is cur-
rently being investigated and compared to seasonal mal-
aria chemoprevention (SMC) in clinical studies in
Burkina Faso and Mali [14]. Seasonal transmission of
malaria due to rainfall patterns is common in the sub-
Sahelian region [15], and novel seasonal preventive tools
could be of great value in many endemic countries.
To reach and maintain pre-elimination prevalence
levels, the entire population of all ages needs to be pro-
tected from infection, rather than children only. Mass
Drug Administration (MDA) can accelerate prevalence
reduction by clearing infections over a short time period,
but the chemo-preventative effect is relatively short-
lived. MDA is also unlikely to interrupt malaria parasite
transmission, since prevalence reduction is transient and
likely to be followed by malaria resurgence [16–18].
MDA is currently implemented in Zambia alongside re-
active case detection [19], and being considered in the
Strategy for Elimination in the Greater Mekong Sub-
region (2015–2030) to combat drug resistance [20], and
to address migrant and mobile populations such as for-
est workers in regions of Cambodia [21].
An alternative to SMC or MDA with drugs alone is to
combine them with vaccines in seasonal settings. To
date little has been done to estimate the impact of add-
ing RTS,S or a similar AIV to existing mass treatment
strategies. Previous modelling predicted that a long dur-
ation of protection is critical for sustained reduction of
malaria transmission via mass vaccination [22], so com-
bination with other interventions is expected to be crit-
ical for effective mass vaccination with the existing or
future AIVs which have limited duration of protection.
There has been no clinical trial combining MDA with
an AIV, although drug and vaccine efficacy profiles are
known from field trials. Investigating novel applications
of existing interventions requires understanding the
likely impact over a large number of possible strategies
and delivery paths, and it is not feasible to test all com-
binations in the field. Modelling and simulation lend
themselves to providing evidence before moving to dem-
onstration field studies [16]. In this study, we used an
existing individual based model of malaria dynamics to
understand the role, and potential public health benefits,
of an AIV delivered through mass administration alone
or in combination with drugs, in a seasonal setting. We
estimated the benefits of mass vaccination with respect
to elimination, transmission reduction, resurgence, and
prevention, for a range of prevalence and health system
settings. These modeling outcomes were compared to
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those produced by modeling use of MDA alone, to esti-
mate the potential for vaccination in addition to treat-
ment to accelerate prevalence reduction or interruption
of transmission, and to estimate the effect of mass vac-
cination on resurgence rates. In order to consider likely
next generation AIVs, we considered two AIVs with dif-
ferent protection profiles, a vaccine with equivalent pro-
tection profile to RTS,S/AS01 and a vaccine with a
longer duration of protection compared to RTS,S/AS01.
Methods
Model and setting details
Malaria transmission and intervention dynamics were
simulated using OpenMalaria [23], an individual-based
simulation model of malaria transmission detailed in
[24] and [25]. Briefly, OpenMalaria combines an
individual-based model of malaria in humans [24] with a
deterministic model of malaria in mosquitoes [26]. The
simulation model includes sub-models of infection of
humans [27], blood-stage parasite densities [28], infec-
tiousness to mosquitoes [29], incidence of morbidity and
mortality [30, 31]; and immunity is separated in pre-
erythrocytic and blood-stage immunity.
A range of transmission levels were investigated by
varying the initial entomological inoculation rate (EIR)
from 0.5 to 5 which approximates PfPR2–10 of 1–20%,
depending on the underlying case management (Add-
itional file 1: Figure S10). This is intended to correspond
to the residual EIR conditional on vector control mea-
sures already in place, which are assumed to remain
constant throughout the duration of the simulations.
The yearly transmission pattern was chosen as an arche-
typal highly seasonal setting with a transmission season
of 3 months (roughly equating to Senegal where SMC is
ongoing [14]). Routine case-management levels were
modelled as the 14 day effective treatment coverage (E14)
with a range of 15–80% (typifying both current levels of
case management in the vast majority of African coun-
tries [32], as well as optimistic scale up of health system
improvements). If not otherwise specified, results in the
main analysis correspond to E14 = 45%. Three levels of
imported infections were investigated when analyzing re-
surgence (0, 2 and 20 infections per 1000 population). A
population of 10,000 individuals was assumed, and 10
stochastic realizations of the model were simulated for
each strategy and setting combination (total of 847,000
simulations). Initial parasite prevalence levels in 2–10
year olds (PfPR2–10), levels of effective access to care
(E14), and timing and coverage levels of the interventions
are summarized in Additional file 1: Tables S1 and S2.
Intervention properties
Intervention properties for both vaccination and MDA,
are summarized in the Additional file 1: Table S1, and
Fig. 1. The underlying parameterization of the vaccine was
informed by previous model fitting to RTS,S/AS01 Phase
3 trial results [13], and should be considered to encompass
vaccine parameterizations of other AIV in development.
The clinical trials reported an observed efficacy against
clinical cases in children receiving four doses (5–17
months of age at first dose) of 43.9% (95% CI 39.7–47.8%)
over 32months of follow-up, and with a decline over time
[33], which was the basis for fitting the vaccine efficacy for
our microsimulations [13]. The action of an AIV in our
microsimulation is to prevent infections, which has a con-
sequential effect on preventing clinical disease. The under-
lying vaccine efficacy against infection in time (including
likely decay of effect), defined as the proportionate reduc-
tion in force of infection assuming beta distributed vari-
ation in efficacy, was parameterized via fitting of our
microsimulation to extensive Phase 3 clinical trial data of
RTS,S/AS01 and has been described elsewhere [7]. Briefly,
AIVs are modelled in Openmalaria as preventing new in-
fections via stochastic process with the probability of pre-
venting an infection referred to as the efficacy against
infection (also the proportion of blood-stage infections
averted). The time course of efficacy was described as a
weibull function capturing possible exponential, biphasic
and step-like decays. This decay function is described via
the following equation:
ε ¼ ε0 exp − log2ð Þ
1
k t
Lk
 !
;
where ε0 is the initial value of efficacy against infec-
tion, L is the half-life of decay (time till efficacy against
infection is half of the initial value), and parameter k in-
forms the shape of the decay (k = 1 is exponential).
Bayesian MCMC was used to compare simulated inci-
dence and Phase 3 trial incidence in order to find the
most appropriate vaccine properties in OpenMalaria de-
fined as efficacy against infection. Models were simultan-
eously fitted to both control and vaccinated incidence
from the trial, and estimates of vaccine properties, site-
specific access to care, and the extent of within-site vari-
ability were obtained.
This model fitting resulted in an estimated efficacy
against infection to be high following immunization,
91% [8], and this efficacy wanes quickly over time result-
ing in limited duration of protection with the half-life
against infection, L, of less than 1 year (efficacy of 45.5%
at 7.3 months, and k = 0.69 describing the shape of effi-
cacy decay) [7, 8]. This half-life refers to time in which
protection against infection has decayed to half the value
of the initial level. We note decay of this protection is bi-
phasic so that protection continues after this time and
decays more slowly than the first 7 months (Fig. 1). This
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efficacy parametrization is in alignment with the esti-
mates of other modelling groups [13]. In addition to this
vaccine parametrization, we have investigated a vaccine
with longer duration of protection with a half-life of 1.5
years, and in a subset of settings a vaccine with lower ef-
ficacy, reducing initial efficacy against infection from 91
to 50% (Additional file 1: Table S1, and Fig. 1). The
fourth dose of the vaccine, and the fifth dose in the 3
years deployment strategies, is assumed to have the same
efficacy profile and coverage as the third dose.
Strategies including MDA were implemented in the
model with Dihydroartemisinin piperaquine (DHAp),
which has slightly lower treatment failure rates than
arthemeter-lumefantrine [34] and was the main mass
drug used in southern Zambia field studies assessing the
short term impact of MDA [35].
Deployment strategies
The strategies simulated were 1) deployment of mass
vaccination of an initial 3 doses in the first year delivered
to population older than 6months of age at first dose
(minimum 9months old at 3rd dose) with 3 monthly
spaced doses and yearly single dose vaccination follow-
ing first year for 2 or 3 years; 2) deployment of MDA of
up to 3 monthly rounds per year delivered to ages from
6months old for 2 or 3 years; or 3) the combination of
both interventions (Additional file 1: Table S2). MDA
was assumed deployed at the beginning of the transmis-
sion season, with an optimistic strategy of 2 additional
rounds deployed at 1 month intervals during the trans-
mission season. Either all 3 MDA rounds were imple-
mented every year of the intervention up to 3 years, or
only the first round was kept for the following year(s).
The vaccine was delivered either prior (with the 3rd
dose completed at the beginning of the season) or dur-
ing the transmission season, the latter possibly favored
for logistical reasons as a fewer number of intervention
rounds in the combination strategies are required as-
suming drug and vaccination are delivered at the same
time. Vaccination coverage represents the proportion of
population receiving all three doses, with no efficacy as-
sumed if receiving less than 3 doses in the first year. The
Fig. 1 Main simulated strategies and drug and vaccine efficacy profiles. a Illustrated strategies: MDA alone, vaccine alone, or MDA with vaccine.
MDA application alone is 3 rounds coinciding with the pattern of seasonal transmission, with 2–3 years of 3 rounds or 3 rounds for only the first
year followed by 1–2 years of 1 round at the beginning of the transmission season; RTS,S-like-duration vaccine or longer duration vaccine
application alone is 3 rounds coinciding with the pattern of seasonal transmission with 1–2 years of 1 dose at the beginning of the season or as
3 rounds before the pattern of seasonal transmission, with 1–2 years of 1 dose at the beginning of the season; and strategies combining MDA
with RTS,S-like-duration vaccine or longer duration vaccine are a combination of all MDA and vaccine implementations combined together. b
Efficacy against infection profiles of 2 years of intervention with MDA, RTS,S like vaccine, vaccine with longer duration of protection, and vaccine
with lower initial efficacy. x-axis represents the time in months, and efficacy against infection is indicated on the y-axis for MDA given at 1
months interval during 3 months the first year and 1 (yellow) or 3 (orange) rounds the second year, and for mass vaccination with a RTS,S like
vaccine (purple), a longer duration protection vaccine (pink), or vaccines with lower initial efficacy against infection (dashed lines). Mass
vaccination is delivered either before the peak of transmission the first year (bottom plot) or during the transmission season (middle plot). The
first year 3 doses of vaccination are administered, but only the 3rd dose of vaccination is modeled, and the second year only one dose is
administered. Initial efficacy against infection for both vaccines are 91% or 50% and the half-life, which is the time in which protection against
infection has decayed to half the value of the initial level, is 7.3 months for the RTS,S like vaccine and 18 months for the vaccine with extended
duration of protection, indicated with arrows on the diagram. Period of peak transmission are indicated by black boxes
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proportion of the population receiving a drug or vaccine
(full 3 dose regimen) was randomly allocated for each
round and intervention given coverage in the default set-
ting, and in a subset of simulations, the vaccine and
MDA, when delivered simultaneously, was administered
to the same population for a given coverage. A range of
coverages from 40 to 100% were considered.
Outcome measured as prevalence reduction
We estimated the relative reduction in prevalence
achieved using different intervention deployment as the
prevalence reduction predicted to be reached each year
in a given setting, namely Dt ¼ 100ð1− PsðtÞPcðtÞÞ, where Dt is
the relative reduction of the mean prevalence at year t of
strategy s; Ps(t) the prevalence at time t of strategy s and
Pc(t) the prevalence at time t of the control strategy. The
relative maximum prevalence reduction, directly follow-
ing the intervention deployment, is simply max(Dt).
Outcome measured as interruption of transmission and
estimated synergistic behavior of the combined
intervention
To estimate the chances of an intervention strategy to
achieve elimination in our model we calculated the
proportion of simulations achieving interruption of
transmission over all stochastic realizations for each
setting. The synergistic behavior of MDA combined
with mass vaccination in chances to reach elimination
was evaluated. The combined mass vaccination with
MDA interventions were considered synergistic if
the chance to interrupt transmission was greater
than the sum of the separate interventions and was
defined consistent with previous disease intervention
analyses [36]. The level of synergy for differing
coverages and transmission settings was calculated
as σ ¼ ð Φcombined−ΦcontrolðΦMDA−ΦcontrolÞþðΦvaccine−ΦcontrolÞÞ−1, where ϕ represents
the probability of interrupting transmission in a simu-
lation set denoted in the subscript, namely with no
intervention (control), MDA alone (MDA), mass vac-
cination alone (vaccine), or the combined MDA and
vaccination (combined). Values of σ greater than 0
represent synergism so that the estimated effect of the
two combined interventions is greater than additive,
values of 0 imply the combined interventions are not
more than additive, and values less than 0 imply less
than additive or maximum level was reached by one
or both single interventions.
Outcome measured as the rate of resurgence
Where no elimination occurred, we estimated the time
it takes after the mass interventions cease for prevalence
to return to initial levels, by estimating resurgence rates.
The rate of resurgence was assumed to follow a
sigmoidal curve and was defined as Rt ¼ PcðtÞ−PsðtÞPcðtÞ−Pmin ∝
ð1þ xbλ50 Þ
−1
, where Pmin is the minimum prevalence
reached by strategy s, λ50 is the estimated half-life of re-
surgence or time till 50% resurgence representing the
years after maximum prevalence reduction was reached
in which prevalence resurges by 50% of the reduction,
and b is the Hill’s slope, representing the steepness of
the logistic curve. Similarly, we estimated λ10 is the time
till 10% resurgence representing the years after max-
imum prevalence reduction was reached in which preva-
lence resurges by 10% of the reduction. Resurgence
parameters were estimated for strategies with 60% cover-
age for 2 years of deployment.
Results
Impact on time course of prevalence
Use of a vaccine with equivalent protection profile to
RTS,S/AS01 (with high initial efficacy, waning over time
reaching half of initial efficacy after 7.3 months) fitted to
the Phase 3 clinical trial data [33], or an AIV with longer
duration of protection (same initial efficacy but with ex-
tended duration of protection, reaching half of initial ef-
ficacy after 18 months), or an AIV with lower initial
efficacy against infection of 50%, was compared to MDA
as single mass interventions alone or in combination,
over 2 to 3 years of intervention, as schematized in Fig.
1a, with efficacy profiles illustrated in Fig. 1b. Example
time courses of predicted all age prevalence before and
after 2 years of mass intervention are illustrated for one
simulation from each strategy and across all simulations
as average yearly prevalence (Fig. 2, variability shown by
minimum and maximum range) (additional strategies
shown in Additional file 1: Figures S1–S2). The differ-
ence between intervention strategies is most distinguish-
able at the annual peak of prevalence. MDA and/or
mass vaccination strategies are found to effect preva-
lence in one of two ways, either the strategy successfully
interrupts transmission, or the strategy leads to a rapid
drop in prevalence followed by malaria resurgence back
to initial prevalence levels.
Relative prevalence reduction
The impact of different intervention strategies was esti-
mated by comparing the relative reduction in prevalence
achieved each year, defined as the yearly prevalence re-
duction measured for each intervention strategy relative
to the prevalence in the control strategy (i.e. no inter-
vention deployed). MDA alone was predicted to be more
effective than mass vaccination alone in reducing preva-
lence, and thus also avoiding resurgence, (Fig. 3a), in set-
tings with different initial prevalence levels (EIR) and
case management levels (E14) (Additional file 1: Figure
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S4). Vaccination only strategies in which three doses of
vaccine were given prior to seasonal transmission in the
first year resulted in larger reductions in prevalence
compared to when delivered during the first season (Fig.
3a and Additional file 1: Figure S4). For combined inter-
vention strategies of mass vaccination added to MDA,
the predicted relative maximum prevalence reduction
achieved was higher compared to strategies deploying
MDA alone (Fig. 3b-e), with a predicted higher preva-
lence reduction when the drug and vaccine was deliv-
ered independently from each other (random coverage,
Fig. 3b-c) compared to when given simultaneously to the
same people (same coverage, Fig. 3d-e). Delivering the 3
doses of vaccine prior to seasonal transmission the first
year instead of during the seasonal transmission had lit-
tle value (Fig. 3b-c)). MDA alone achieved large reduc-
tions in prevalence, especially at higher coverage levels
and low transmission levels, such that adding mass vac-
cination had only a limited relative impact on prevalence
reduction at these higher coverage levels (Additional file
1: Figure S5).
Interruption of transmission
The proportion of simulations achieving interruption of
transmission for each strategy was calculated over all
stochastic realizations for each setting. Assuming 60%
coverage and 2 years of intervention, interruption of
transmission occurred in 10% of the control simulations
with initial PfPR2–10 less than 1%, highlighting possible
stochastic extinction in the models at very low preva-
lence [17]. Interruption of transmission for all strategies
was dependent on initial PfPR2–10 with proportion of
simulations in which transmission was interrupted de-
creasing with increasing initial PfPR2–10 (Fig. 4a-b), and
thus interruption of transmission was more likely in a
setting where vector control is already at high coverage
(expressed in this study as low initial prevalence). Inter-
ruption of transmission was less likely to occur with
lower case management (Additional file 1: Table S5 and
Figure S6), with MDA, mass vaccination or combined
strategies more likely to interrupt transmission if effect-
ive access to care is higher. Excluding simulations with
initial PfPR2–10 under 1% where stochastic extinction
Fig. 2 Example time course of predicted all age prevalence following intervention. Single simulation examples (chosen at random) of estimated continuous
(upper plots) and median and range of estimated yearly average (lower plots) all age prevalence following different intervention strategies deployed during
2 years. a estimated all age prevalence following mass vaccination (purple) or mass vaccination with longer duration vaccine (pink), b estimated all age
prevalence following full rounds of MDA alone (orange) or in combination with mass vaccination (green) or mass vaccination with longer duration vaccine
(blue). Intervention coverage of 60% was assumed, with an initial yearly average PfPR2–10 = 4% with peak PfPR2–10≈ 10–15% (corresponding to an initial EIR of
2 and effective access to care E14 = 45%). Full description of the different strategies can be found in Additional file 1: Table S2
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can occur, mass vaccination alone did not lead to trans-
mission interruption when using RTS,S-like-duration
vaccine and led to transmission interruption in 20% of
the simulations in settings of initial PfPR2–10 of 2% when
using the vaccine with longer duration of protection
(Fig. 4a). With a vaccine of lower vaccine efficacy (50%),
no interruption of transmission for PfPR2–10 higher than
1% was observed. Similarly, at initial PfPR2–10 of 2% the
proportion of simulations with transmission interruption
was 20% for strategies deploying MDA alone. For initial
PfPR2–10 greater than 4%, transmission interruption was
less likely for both vaccination alone and MDA alone
(Fig. 4a-b). Combining both interventions at 60% cover-
age, the highest proportion of simulations in which
interruption of transmission was achieved for 2 years of
intervention was estimated for initial PfPR2–10 range 2–
4%, with interruption of transmission estimated at 75%
for strategies deploying MDA combined with
immunization with a vaccine with equivalent protection
properties to RTS,S/AS01, and of 80% when combined
with the vaccine with longer duration of protection (Fig.
4b). Including a 3rd year of intervention in these settings
increased the proportion to 95–100%, even assuming a
coverage of 60% (Additional file 1: Table S3). Combining
MDA with a vaccine with lower efficacy resulted in
lower chances to interrupt transmission compared to
combined strategies with a vaccine with higher efficacy
profile, however, for a PfPR2–10 of 2%, this lower efficacy
Fig. 3 Relative maximum prevalence reduction achieved immediately following 2 years of intervention for different intervention coverages.
Estimated maximum prevalence reduction achieved (proportion, where 0 indicates no prevalence reduction and 1 interruption of transmission)
for coverage levels 40–100% (x-axis) by a single interventions, b-d combined interventions with drugs and vaccination given independently, and
d-e combined interventions with drugs and vaccination given to the same population when administered simultaneously. a Compares MDA or
mass vaccination alone: mass vaccination (purple) before (dashed lines) or during (solid lines) transmission season and full rounds of MDA
(orange) or reduced rounds of MDA (yellow); b and d Compare reduced rounds of MDA (yellow) with combined strategies of mass vaccination
before (dashed lines) or during (solid lines) the transmission season together with full rounds of MDA (brown); and c and e Compare reduced
rounds of MDA (orange) with combined strategies of mass vaccination before (dashed lines) or during (solid lines) the transmission season
together with full rounds of MDA (green). Each intervention is represented by the median and minimum-maximum range across 10 simulations
per a strategy. Initial average PfPR2–10 = 4% with peak PfPR2–10 ≈ 10–15% (corresponding to an initial EIR = 2 and effective access to
care E14 = 45%)
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vaccine when combined with MDA increased the
chances of interrupting transmission from 20 to 60%
and from 20 to 70% with longer duration vaccine com-
pared with using MDA only (Additional file 1: Figure
S7). Administering the vaccine and MDA simultan-
eously to the same population for a given coverage
level resulted in slightly lower predictions of chances
to interrupt transmission than with random coverage
between the two interventions (Additional file 1: Fig-
ure S6). Proportions of simulations with transmission
interruption were similar for strategies vaccinating the
population before the transmission season or during
the transmission for mass vaccination or combined
interventions, even if slightly higher when vaccinating
Fig. 4 Interruption of transmission and synergism for different intervention strategies. a-b Proportion of simulations in which interruption of
transmission is estimated to be achieved with mass vaccination (a) or MDA combined with mass vaccination compared to MDA only (b). Initial
PfPR2–10 (%) levels are shown on the x-axis, and proportion of the simulations falling into each category are shown on the y-axis. All interventions
were deployed for 2 years at a coverage of 60%. Categories of simulations are i) interruption of transmission occurred with no intervention at all,
due to very low initial prevalence (black), ii) interruption of transmission occurred with single interventions, namely with mass vaccination with
RTS,S like vaccine (purple) or longer duration vaccine (pink), or with MDA (orange), iii) interruption of transmission occurred only adding mass
vaccination to MDA (green and blue using with RTS,S like vaccine or longer duration vaccine respectively), and iv) resurgence occurred and no
interruption of transmission was achieved (grey).c Estimated synergy coefficient (σ) of the combined mass vaccination and MDA intervention in
regards probability to interrupt transmission. The x-axis indicates coverage levels of MDA, and the y-axis coverage levels of mass vaccination, and
the level of synergy between the two intervention strategies are indicated in colour. Blue represents synergistic behavior (> 0) in the combined
MDA and mass vaccination, light green represents values of 0 which imply the combined interventions are not more than additive, and yellow to
red colours represent values less than 0 which imply less than additive or maximum level was reached by one or both single interventions. Grey
areas represent settings where resurgence occurred in all simulation, thus no synergy could be calculated. The synergy coefficient are shown for
the combination of MDA with RTS,S like vaccine (upper row) and MDA with the longer duration vaccine (bottom row), and for different levels of
initial PfPR2–10 (%) (columns)
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before the season (Additional file 1: Table S3). Fur-
ther results can be found in Additional file 1: Tables
S3-S5.
Synergism, defined as observing a greater propor-
tion of simulations with interrupted transmission in
the combined interventions than in the sum of the
single interventions (see methods), was calculated for
a range of initial PfPR2–10 and intervention coverage
levels (Fig. 4c and Additional file 1: Figure S7 and
Figure S9). The lower the initial PfPR2–10, the less
likely synergism was observed, as the chances to
interrupt transmission using MDA as a single inter-
vention was higher. Similarly, increasing case manage-
ment or increasing MDA coverage decreased
synergism between the two interventions. Increasing
vaccine coverage or duration of protection increased
the chances to interrupt transmission but did not
have an obvious effect on synergism. The lower initial
vaccine efficacy decreased the number of settings
where synergism was predicted (Additional file 1: Fig-
ure S7). Synergism was predicted for both scenarios
of when the interventions were delivered
independently from each other or simultaneously to
the same target population (Fig. 4c and Additional file
1: Figure S7).
Resurgence
Resurgence occurs in each simulation in which transmis-
sion was not interrupted with prevalence eventually
returning to initial levels. Additional to predicting the
chances to achieve transmission interruption (or risk of
resurgence), we estimated the time to resurgence after
deployment of the intervention cease. This time reflects
a period where prevalence remains at very low levels and
other interventions such as reactive case detection (not
simulated here) could potentially be effective to inter-
rupt transmission. In settings of initial PfPR2–10 = 9% re-
surgence occurred in all simulations, and the estimated
resurgence half-life, λ50, was lowest for the MDA strat-
egy (median λ50 = 1.83 years), whereas for the strategy
combining MDA with mass vaccination with RTS,S-like-
duration vaccine λ50 was more than 2.5 years longer than
MDA alone (median λ50 = 3.68 years) (Fig. 5 and Add-
itional file 1: Table S6). The estimated Hill’s slope
Fig. 5 Resurgence following 2 years of deployment of different interventions at PfPR2–10 = 4 and 9%. a Predicted relative resurgence at initial
PfPR2–10 = 9% (EIR = 2 and E14 = 45%) with 95% confidence intervals estimated from fitting a 4-parameter logistic regression to the pooled
simulations for strategy MDA alone (orange), mass vaccination alone (purple), mass vaccination with a longer duration vaccine (pink), MDA
combined with mass vaccination (green) and MDA combined with a longer duration vaccine (blue). b The average minimum prevalence in the
total population reached directly following each intervention. c-d Summarized parameters describing resurgence (boxplots with median and 95%
confidence intervals) estimated from the logistic regressions to each simulations for each strategy are the estimated half-life or time till 50%
resurgence, λ50, representing the years after maximum prevalence reduction was reached in which prevalence resurges by 50% of the reduction
and the time till 10% resurgence, λ10, representing the years after maximum prevalence reduction was reached where prevalence resurges 10%
of the reduction. The estimates are shown for initial PfPR2–10 = 9% in c and for initial PfPR2–10 = 4% in d. The corresponding number of
simulations with resurgence per strategy and setting are indicated at the top of each summary boxplot
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(median 3.55) was also higher, as was λ10 (increased by
1.28 years), defined as the time after maximum preva-
lence reduction was reached in which prevalence re-
surges to 10% of the reduction, indicating that
resurgence was delayed in the combined strategy and
prevalence remained lower for a longer time period of
time compared to MDA alone. Half-life of resurgence
were similar in the strategies where mass vaccination
was performed before the transmission season, with no
evident increase (Additional file 1: Table S6). For strat-
egies with MDA combined with mass vaccination using
a vaccine with equivalent protection profiles to RTS,S/
AS01, the half-life of resurgence was increased by 1.28
years if the interventions were deployed for 3 years in-
stead of 2 years.
For initial PfPR2–10 of 4%, resurgence parameters were
calculated for 80% of the simulations in which resur-
gence occurred. In the strategy combining MDA with
mass vaccination using a vaccine with equivalent protec-
tion profile to RTS,S/AS01, λ50 was estimated to be
more than 2 years longer than MDA alone (median
λ50 = 6.78 years compared to median λ50 = 4.63 years)
(Fig. 5 and Additional file 1: Table S6), and the time
after maximum prevalence reduction was reached in
which prevalence resurges to 10% of the reduction in-
creased by 1.48 years (median λ10 = 3.46 against median
λ10 = 1.98 for MDA only).
Overall, delivering the vaccine to the same people as
receiving MDA produced similar estimates of resurgence
rates for both prevalence levels investigated (Additional
file 1: Table S6). Using a vaccine with lower initial effi-
cacy in the combined strategies had less impact in delay-
ing resurgence but nevertheless the resurgence half-life
was estimated to be increased by almost a year com-
pared to using MDA only (Additional file 1: Table S6).
Simulations that assumed increased levels of imported
infections resulted in decreased estimates of resurgence
half-life, however the estimated resurgence rates
remained lower for the combined strategies compared to
MDA alone (Additional file 1: Table S6). Increasing
levels of case management decreased proportion of sim-
ulations where resurgence occurred (Additional file 1:
Table S6).
Vaccination to reduce years of mass deployment and
reduce number of MDA rounds
Adding mass vaccination to MDA strategies of 2 years
resulted in a similar or higher proportion of simulations
with interruption of transmission in a shorter time
period of intervention than compared to MDA deployed
for 3 years. This was true when MDA and vaccination
was administered simultaneously to the same people and
when given independently from each other (random
coverage between both interventions) (Table 1). For
PfPR2–10 = 2–4%, the proportion of simulations in which
interruption of transmission occurred was 30% higher in
strategies combining RTS,S-like-duration mass vaccin-
ation with full rounds of MDA for 2 years (65%
Table 1 Percentage of simulations in which interruption of transmission occurred for different strategies and deploy times
Strategies Interrupted transmission [%]
PfPR2–10 [%]
2 4 5 7
3 years full MDA rounds 80 20 0 0
2 years full MDA rounds + vaccine 90 40 0 0
100A 40A 0A 0A
2 years full MDA rounds + longer duration vaccine 100 60 30 0
80A 40A 30A 0A
2 years full MDA rounds + vaccine lower efficacy 60 0 0 0
30A 0A 0A 0A
2 years full MDA rounds 20 0 0 0
2 years reduced MDA rounds + vaccine 70 10 0 0
70A 0A 0A 0A
2 years reduced MDA rounds + longer duration vaccine 90 70 0 0
80A 10A 0A 0A
2 years reduced MDA rounds + vaccine lower efficacy 30 0 0 0
30A 0A 0A 0A
Percentage of resurgence in the simulations are shown for interventions (rows) at 60% coverage, for 2- and 3- years of full rounds of MDA, and 2 years of full or
reduced rounds of MDA combined with mass vaccination with RTS,S like vaccine (initial efficacy against infection 91%, half-life 0.61 years), longer duration of
protection vaccine (half-life 1.5 years), or lower initial efficacy (50%). Results are shown for different levels of initial PfPR2–10 (%) (columns), and results where the
vaccine is given to same proportion of the population than the simultaneous MDA are indicated with A
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transmission interruption) compared to 3 years of full
MDA rounds only (50% transmission interruption)
(Table 1). For MDA combined with longer duration vac-
cines, we estimated 80% of simulations interrupted
transmission (Table 1). For MDA combined with a vac-
cine of lower initial efficacy (50%), we predicted 3 years
of MDA to have greater chances to interrupt
transmission.
Adding mass vaccination to MDA could replace 2
rounds of MDA in the second year for similar or im-
proved chances of interruption of transmission, espe-
cially at lower prevalence levels. For PfPR2–10 = 2% the
proportion of simulations with interrupted transmission
was 70% if 2 years of reduced rounds of MDA combined
with mass vaccination was deployed (namely 3 rounds of
MDA plus vaccination the first year and only 1 round of
MDA plus vaccine the second year) compared to an
interruption of transmission of 20% in strategies of 2
years of 3 rounds of MDA only (Table 1). Using a longer
duration vaccine, 2 years of reduced rounds of MDA
combined with mass vaccination at PfPR2–10 = 2% led to
a proportion of simulations with interrupted transmis-
sion up to 90% (Table 1). A vaccine with a lower initial
efficacy of 50% could replace 2 rounds of MDA in the
second year, but in both scenarios (vaccine and MDA
with reduced rounds or full round of MDA) chances to
interrupt transmission remained low (Table 1).
Simulations where MDA coverage was 60% but vac-
cine coverage was 40% in the combined interventions
were additionally compared. In settings of PfPR2–10 = 1–
4% the proportion of simulations with transmission
interruption was lower for vaccine coverage of 40% com-
pared to 60%, thus increasing proportion with resur-
gence (Additional file 1: Table S3 and S4). However,
even a strategy with a lower coverage of vaccination at
40%, combination strategies (mass vaccination and
MDA) deployed during 2 years remained more favorable
compared to using 3 years of MDA alone (Additional file
1: Table S3 and S4).
Discussion
Given the enormous multiplicity of combinations of in-
terventions that might be considered when targeting the
whole population with combination strategies, and given
the expense of mass deployment, it is critical to carry
out in silico investigations of the potential of novel de-
ployment options in order to avoid wasteful field trials
of fruitless combinations [37].
To date little has been done to estimate the impact of
adding a similar AIV to existing mass treatment strat-
egies. By combining mass vaccination to treatment, the
infectious reservoir is reduced by clearing infections in a
large proportion of the population via MDA, and adding
an intervention with ability to prevent infections for
longer than the duration of the transmission season
(even with waning protective immune responses restored
with yearly immunizations) resulted in higher maximum
prevalence reduction, increased chance of elimination,
and importantly, delayed resurgence compared to inter-
ventions without the vaccine. Our simulations suggest
that combining MDA with an AIV has a synergistic ef-
fect in regards to chances to interrupt transmission, and
synergism increased with greater levels of initial preva-
lence and lower MDA coverage or case-management.
Synergism can be the result of deploying two interven-
tions which increases overall coverage of the population
covered by at least one intervention, but as synergism
was also predicted when the vaccine and the drug were
given to the same people given coverage, although in a
lesser extent, it is also likely a consequence of the inter-
ventions targeting different parasite life stages.
It will be important to consider whether the ap-
proaches modelled here are operationally feasible and
what level of health system and program strength is re-
quired to coordinate vaccination and drug campaigns.
For this reason, we investigated a range of coverages and
our main results were presented for coverages of 60%,
assuming any higher was too optimistic. In those condi-
tions, with initial PfPR2–10 = 4%, we found that for the
simulations where transmission is not interrupted, the
rate of resurgence is halved compared to MDA alone,
extending the resurgence half-life up to two and a half
years. Alternatively, we investigated a higher MDA
coverage compared to vaccination and we found that
adding mass vaccination even at a lower coverage (40%)
remained beneficial in delaying resurgence and reducing
MDA rounds. We also found limited differences in im-
pact between the combined strategies with vaccination
before or during the transmission season, arguing for a
preference of during the season with 3 visits as opposed
to more visits.
In addition, we estimated that vaccines of longer dur-
ation of protection can further delay resurgence, arguing
that research into the feasibility of increasing longevity
of protection of a vaccine has importance for the elimin-
ation strategies investigated here.
The addition of mass vaccination to MDA, compared
with MDA alone, has the potential to reduce the number
of MDA rounds needed, as well as the number of years
that interventions may be needed, to achieve similar
public health benefits of prevalence reduction and
chances to interrupt transmission, and thus reduce the
length of deployment of interventions from 3 to 2 years.
Reducing the length of overall intervention deployment
has the potential to reduce the number of mass inter-
vention visits, and thus costs of visits. Moreover, al-
though an economic analysis was outside the scope of
this study, a shorter period of deployment could be
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beneficial to national malaria control and elimination
strategies facing budgetary constraints. Although this
work did not explicitly explore mobility, we did model
importations of infections and highly mobile populations
will limit operational coverage of the vaccines and MDA.
Limited duration mass interventions are not intended to
tackle importation. As with MDA, importation is likely
to have little effect on the estimated prevalence reduc-
tion unless initial prevalence is very low, and in these
settings where interruption of transmission is achieved a
high level of case management will be important to
maintain zero prevalence [16]. In line with this, we
found importation of infections had little effect on
prevalence reduction achieved but that time to resur-
gence decreased as importation increased.
Furthermore, interruption of transmission with mass
interventions is likely only possible for scenarios of low
initial prevalence (low prevalence as a result of vector
control or other interventions), with a high level of case
management and an increase in other intervention tools,
which was recently highlighted by the WHO Malaria
Policy Advisory Committee meeting with regards to the
use of MDA [38]. Our simulations also indicated that,
chances to interrupt transmission increase with higher
case management. This implies that such mass interven-
tions should not be investigated independently of case
management, and that together with vector control or
reactive tools, will play a decisive role in the success of
the interventions to reach elimination and avoid
resurgence.
This work was confined to a limited number of
model-based scenarios of mass interventions and as such
there are several limitations. Firstly, several aspects not
captured might enhance or diminish the impact of mass
vaccination combined with MDA. On a biological level,
vaccination with an AIV with drugs has not been suffi-
ciently investigated, and it is unclear how vaccine effi-
cacy, immune dynamics in response to the vaccine, the
length of protection, or the rate of vaccine failure would
be influenced. Such effects are unknown, however a
lower rate of vaccine failure and longer duration of pro-
tection would delay resurgence and extend the pre-
elimination period, and conversely higher failure rates
would decrease benefits. Additionally, we did not ad-
dress any potential evolutionary effects such as vaccine
insensitivity, nor antigenic sin. However, we note
deploying with treatment may protect against evolution
of vaccine insensitivity.
Secondly, the underlying vaccine assumptions in the
models, including the effect of a forth vaccine dose,
may influence results. Vaccine properties were based
on analysis of the results of RTS,S Phase 3 clinical
trials [13], which targeted infants aged 6 to 12 weeks
and young children aged 5 to 17 months. In the
context of mass vaccination, as the efficacy and pro-
tection might be different for different ages and previ-
ous exposure, extension of the protection profile and
vaccine parameterization from children to the entire
population is a necessary simplification based on cur-
rently available data. A full sensitivity analysis around
vaccine efficacy profiles has not been performed in
this study, but simulations where initial efficacy
against infection for children and adults was reduced
to 50% suggest that this would considerably decrease
the prevalence and case management settings where
the combination strategies would reach very low
transmission levels or interruption of transmission.
Thirdly, we did not model potential increases in vector
control or case management levels over the time of
intervention, either due to vector control campaigns or
active efforts to improve access to treatment or due to a
better efficiency in the health system as fewer cases need
to be treated. Both would further reduce prevalence
levels following mass intervention deployment, and in
some settings, would likely enhance the effect of mass
vaccination, especially during the resurgence period.
Conversely, we did not model deceasing levels of vector
control which may decrease the benefits of the mass
intervention strategies or increase rates of resurgence.
We chose a 3-month seasonal malaria transmission
setting of sub-Sahel African countries approximating the
pattern in Senegal where SMC is ongoing, and investi-
gated the impact on average transmission, not account-
ing for heterogeneities in transmission. Further studies
could be undertaken to tailor the analysis specifically to
a country or region, with corresponding transmission
pattern, heterogeneity, and other underlying settings,
such as case management or adapted timing and dur-
ation of deployment. The impact of interventions may
be sensitive to timing and the seasonal pattern chosen
for malaria transmission, and that the heterogeneity of
transmission across a given region will imply a need for
focal planning.
Previous modeling has shown the impact of MDA is
very sensitive to population size, being best suited for
small populations and with total impact sensitive to the
proportion of the population receiving no treatment
from any of the deployed rounds [39]. In our current
work, individual rounds of MDA were given to a ran-
dom proportion of the population for a given coverage,
mass vaccination was deployed either independently to
MDA or in some settings simultaneously to MDA, and
the 3 vaccine doses independently from the fourth dose.
As expected, scenarios with total correlation between
those covered by MDA and mass vaccination predicted
a slightly reduced impact, but the key determinants
probably remains in the random coverage between
MDA rounds similar to results found for multiple
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rounds of MDA [16], and total correlation between
rounds has not been investigated here. In more realistic
settings the proportion of the population covered would
neither be completely independent nor would it be
exactly the same between deployments, and thus our as-
sumptions might be slightly optimistic so that the nom-
inal coverages we simulate reflect higher values in the
field.
Given that MDA and SMC are currently imple-
mented in several settings [19, 40], and that the com-
bination of RTS,S and SMC is being tested in field
trials [14], we are in a position to consider adapting
these combination of interventions to different ages.
Technical challenges however remain. It is envisioned
that RTS,S may be delivered in much the same way
as meningococcal A conjugate vaccine is being de-
ployed in sub-Saharan Africa in 1–29 year old, ini-
tially in intense mass vaccination campaigns, and then
followed by introduction into existing Extended
Immunization Programmes in the individual countries
[41]. Any vaccines used in malaria elimination cam-
paigns will need to be WHO pre-qualified ensuring
that characteristics are aligned with cold-chain re-
quirements available in the countries where it is de-
ployed [42]. For an AIV to be used as a mass
intervention in Africa or Asia, several important un-
knowns must be addressed with respect to immuno-
genicity in adults and immunogenicity in populations
outside Africa. Measurement of immune responses
and protection in adults have been tested in the Me-
kong, where RTS,S was administered alone or in
combination to drugs [43] as are many other CHMI
(controlled human malaria infection) studies of RTS,S,
R21, and PfSPZ. These studies should provide add-
itional evidence that could be used to model their po-
tential role in mass vaccination scenarios. Other
challenges include safety and efficacy testing when
vaccines are administered with drugs and regulatory
hurdles for use of any of the AIVs for children and
adults, which may be more difficult with new anti-
gens. From an operational perspective, the challenges
may be significant, ensuring sufficient coverage of the
first three or required initial number of doses of the
vaccine. And lastly, to make use of the potential
benefit in delaying resurgence, settings must be pre-
pared with additional interventions during the low
prevalence period following 2 or 3 years of mass
intervention, and as with MDA, it will be important
to include surveillance and response strategies com-
bined with strong health systems to address import-
ation of infection and preserve this delay in
resurgence.
Given combining mass vaccination with treatment has
potential to delay resurgence for longer than treatment
alone, there may be a role in malaria outbreaks or in fra-
gile contexts where health systems are weakened by
other disease outbreaks [44] or conflict. However, the
number of doses required to reach high efficacy may
limit this application. There may also be a role in help-
ing mitigate spread of drug resistance in the Mekong or
for targeting forest workers [37], or for areas in which
residual or outdoor transmission renders indoor residual
spraying less effective, but further investigations are
required.
Our modelling study provides evidence of potential
use of an AIV in malaria elimination with characteris-
tics similar to the most advanced vaccines: high initial
efficacy and with limited duration of protection in an
area with highly seasonal malaria transmission. As-
sumptions in regards to demographics, past history of
malaria, transmission profile, vector species, and
health systems strengths were not geographic specific.
An important next step will be to understand which
settings and countries these mass interventions strat-
egies are feasible for and what range of settings with
pockets of focal transmission. This would include an
assessment of cost-effectiveness.
Conclusion
This work reports modelling outputs of vaccination with
existing and potential forthcoming AIVs combined with
MDA - indicating such a combination could be a pos-
sible strategy to rapidly decrease prevalence and keep
prevalence levels lower than would MDA alone for sev-
eral years before resurgence, thus challenging thinking
on the role of malaria tools already at our disposal. A
deep understanding of current malaria burden and level
of case management, with a cautious investigation of the
timing and operational feasibility of the mass interven-
tions would nevertheless be of paramount importance
before implementing such a strategy for malaria elimin-
ation, as the risk of resurgence and thus failure of the
mass campaigns will remain a threat. Acknowledging
that malaria elimination will not be achieved with a sin-
gle intervention, we should continue to investigate com-
bination intervention strategies targeting different parts
of the lifecycle that will help achieve our goals.
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